Er det efter Kommissionens opfattelse foreneligt med traktatens bestemmelser om varers fri bevægelighed og EF-Domstolens praksis vedrørende parallelimport af medicinalvarer, såfremt nationale domstole begrunder ulovligheden eksempelvis med, at den manglende adgang udelukkende er en kommerciel hindring, der må søges overvundet ved (i princippet ubegrænset) markedsføring over for receptudskrivende læger (på trods af at parallelimportøren ikke har adgang til Drug Master File eller tilsvarende videnskabelige/tekniske oplysninger, og uanset at prisen på lægemidlet er reguleret af regler om udlevering af medicin)?
In the Commission's view, is it consistent with the provisions of the Treaty on the free movement of goods and with Court of Justice case law concerning parallel imports of pharmaceuticals for national courts to justify their ruling that the above practice is illegal on the grounds, for example, that the lack of access to the market is solely a commercial obstacle which importers must seek to overcome by means of (in principle unrestricted) marketing which targets prescribing doctors (despite the fact that parallel importers do not have access to Drug Master Files or equivalent scientific/technical data, and regardless of whether the price of the pharmaceutical is regulated by rules on the dispensing of medicines)?